Posted on April 29, 2011 by Sitemaster
An article just published on-line in Cancer has demonstrated that, in a cohort of men with a median follow-up of > 10 years, salvage radiation therapy (after first-line radical prostatectomy) reduces all-cause mortality in men with short (< 6 months) and longer (≥ 6 months) PSA doubling times at the time of initial biochemical disease progression. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: doubling time, PSA, PSADT, radiation therapy, radical prostatectomy, salvage | Comments Off on Post-surgical salvage radiation therapy and all-cause patient mortality
Posted on April 16, 2011 by Sitemaster
Researchers at Johns Hopkins have attempted to correlate data on PSA doubling time (PSADT) with data on prostate cancer progression in men being treated with intermittent androgen deprivation therapy (IADT) after biochemical recurrence of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen deprivation therapy, doubling time, IADT, intermittent, PSA, PSADT | 1 Comment »
Posted on February 15, 2011 by Sitemaster
It appears that regular use of commercially available pomegranate extract really does have a significant impact on PSA doubling time (PSADT) among men with a rising PSA but no indication of bone metastasis. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, extract, pomegranate, progression, PSA, PSADT | 2 Comments »
Posted on January 19, 2011 by Sitemaster
Earlier studies based on data from Johns Hopkins and the Center for Prostate Disease Research have shown that PSA doubling times are strongly associated with risk for metastasis, prostate cancer-specific, and overall mortality. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, prognosis, PSA, PSADT, risk | 3 Comments »
Posted on December 29, 2010 by Sitemaster
In 2009, at a presentation at the American Society for Clinical Oncology, Antonorakis et al. initially presented data, from the Johns Hopkins database, demonstrating the prognostic significance of PSA doubling time (PSADT) to long-term survival of men with progressive prostate cancer who were otherwise untreated after surgery. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical recurrence, doubling time, metastasis, mortality, prognosis, PSA, PSADT, risk, surgery, survival | 3 Comments »
Posted on July 21, 2010 by Sitemaster
PSA doubling time or PSADT is a valuable prognostic factor in assessing the need for second- or even third-line treatment in men with biochemical progression of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: calculator, on-line, PSA doubling time, PSADT | 5 Comments »
Posted on May 4, 2010 by Sitemaster
The role of PSA kinetics (i.e., PSA doubling time and PSA velocity) in the early diagnosis of prostate cancer and in the monitoring of patients on active surveillance protocols has been controversial. We now have some more definitive data. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, doubling time, kinetics, PSA, PSADT, PSAV, velocity | 6 Comments »
Posted on December 14, 2009 by Sitemaster
Researchers associated with the Duke Prostate Cancer have re-calibrated an older nomogram (used to predict the likelihood of biochemical recurrence after a radical prostatectomy or RP). The revised nomogram is now capable of predicting not only biochemical recurrence but also the much more clinically significant risk for an aggressive recurrence — in which the post-surgical PSA doubling time (PSADT) is < 9 months. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: aggressive, biochemical recurrence, PSA doubling time, PSADT, radical prostatectomy, surgery | Leave a comment »
Posted on November 20, 2009 by Sitemaster
D’Amico and his colleagues demonstrated some time ago that PSA velocity and PSA doubling time (PSADT) are valuable tools in predicting which patients with recurrent prostate cancer after first-line treatment are at greatest risk of metastatic disease and prostate cancer-specific mortality. But they have now shown that PSADT is less predictive of risk in men with other “comorbid” health problems. … READ MORE …
Filed under: Management, Treatment | Tagged: comorbidity, PSA doubling time, PSA velocity, PSADT, recurrence | Leave a comment »
Posted on July 29, 2009 by Sitemaster
A new study from a group at Duke University has attempted to assess whether data based on PSA doubling times in men with PSA levels up to 0.2 ng/ml can be used as effectively to make early treatment decisions for men with a rising PSA after first-line therapy as can PSA doubling times for men with PSA levels higher than 0.2 ng/ml. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: early, PSA doubling time, PSADT, radical prostatectomy, salvage | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 